Teserpaturev is under clinical development by Daiichi Sankyo and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData, Phase I drugs for Malignant Pleural Mesothelioma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Teserpaturev’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Teserpaturev overview

Teserpaturev (Delytact) is a genetically engineered herpes simplex virus type 1 (HSV-1) with triple mutations that expresses augmented viral replication in tumor cells, strong induction of anti-tumor immunity and enhanced safety in normal tissues. It is formulated as solution for intratumor route of administration. Delytact is indicated for the treatment of patients with malignant glioma or any type of primary brain cancer.

Teserpaturev is under investigation for progressive olfactory neuroblastoma and malignant pleural mesothelioma. G-47 Delta was also under investigation for the treatment of recurrent glioblastoma, castration resistant prostate cancer, breast cancer, schwannoma renal carcinoma, and urothelial carcinoma. G-47 Delta is administered by intratumoral route. G-47 Delta is a third generation oncolytic herpes simplex virus type 1 (HSV-1). HSV-1 is the prototype of the a-herpes virus family. G-47 Delta is a triple-mutated, third-generation oncolytic HSV-1 which is developed by introducing an additional genetic mutation to the viral genome of G207, a second generation HSV-1. 

Daiichi Sankyo overview

Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

For a complete picture of Teserpaturev’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.